Henry Schein (HSIC) valuation
Henry Schein P/E ratio history
Henry Schein trades at 24.8 times its earnings over the last twelve months and 14.9 times the earnings analysts expect over the next twelve. At its last 9 fiscal year ends its P/E ranged from 14.1 (year to Dec 2019) to 27.8 (year to Dec 2018), with a median of 23.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 27, 2025 | $76.13 | $3.27 | 23.3 | 14.7 |
| Dec 28, 2024 | $70.42 | $3.05 | 23.1 | 13.9 |
| Dec 30, 2023 | $75.71 | $3.16 | 24.0 | 15.0 |
| Dec 31, 2022 | $79.87 | $3.91 | 20.4 | 16.2 |
| Dec 25, 2021 | $74.93 | $4.45 | 16.8 | 16.5 |
| Dec 26, 2020 | $65.83 | $2.81 | 23.4 | — |
| Dec 28, 2019 | $66.58 | $4.72 | 14.1 | — |
| Dec 29, 2018 | $61.11 | $2.20 | 27.8 | — |
| Dec 30, 2017 | $54.81 | $2.00 | 27.4 | — |
| Dec 31, 2016 | $59.49 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Henry Schein valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Henry ScheinHSIC | $9.67B | 24.8 | 14.9 | 0.7 |
| Universal Health ServicesUHS | $10.7B | 7.2 | 7.5 | 0.6 |
| DaVitaDVA | $12.0B | 13.9 | 11.4 | 0.8 |
| SolventumSOLV | $14.1B | 9.9 | 11.3 | 1.7 |
| Hims & Hers HealthHIMS | $6.41B | — | — | 2.5 |
| Quest DiagnosticsDGX | $27.8B | 25.1 | 21.3 | 2.4 |
| LabcorpLH | $29.6B | 29.7 | 18.6 | 2.1 |
| CenteneCNC | $33.8B | 22.7 | 12.6 | 0.2 |
| HumanaHUM | $49.8B | 39.1 | 31.6 | 0.3 |
| Peer median | 22.7 | 12.6 | 1.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: HSIC financials · HSIC returns
No forecast, no recommendation. This page describes Henry Schein from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.